We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.80 | -3.37% | 195.20 | 193.00 | 194.20 | 204.00 | 193.00 | 204.00 | 158,380 | 16:35:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.14 | 187.17M |
From Apr 2019 to Apr 2024
TIDMOXB
RNS Number : 8814G
Oxford Biomedica PLC
01 June 2017
Oxford BioMedica
Total Voting Rights
Oxford, UK - 1 June 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 31 May 2017 consisted of 3,088,420,525 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 3,088,420,525.
The above figure (3,088,420,525) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.
- Ends -
For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 John Dawson, Chief Executive Officer 783 000 Tim Watts, Chief Financial Officer Consilium Strategic Communications Tel: +44 (0)20 Mary-Jane Elliott/Matthew Neal/Chris 3709 5700 Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAFKFEAEXEFF
(END) Dow Jones Newswires
June 01, 2017 07:22 ET (11:22 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
